Annual accounts receivable:
$38.38M+$5.46M(+16.58%)Summary
- As of today (May 23, 2025), LGND annual accounts receivable is $38.38 million, with the most recent change of +$5.46 million (+16.58%) on December 31, 2024.
- During the last 3 years, LGND annual accounts receivable has fallen by -$47.08 million (-55.09%).
- LGND annual accounts receivable is now -55.09% below its all-time high of $85.45 million, reached on December 31, 2021.
Performance
LGND Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$38.49M+$116.00K(+0.30%)Summary
- As of today (May 23, 2025), LGND quarterly accounts receivable is $38.49 million, with the most recent change of +$116.00 thousand (+0.30%) on March 31, 2025.
- Over the past year, LGND quarterly accounts receivable has increased by +$10.06 million (+35.37%).
- LGND quarterly accounts receivable is now -54.96% below its all-time high of $85.45 million, reached on December 31, 2021.
Performance
LGND Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
LGND Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +16.6% | +35.4% |
| 3 y3 years | -55.1% | -7.9% |
| 5 y5 years | +26.3% | -2.6% |
LGND Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -55.1% | +26.1% | -40.9% | +37.5% |
| 5 y | 5-year | -55.1% | +26.3% | -55.0% | +37.5% |
| alltime | all time | -55.1% | +6109.7% | -55.0% | >+9999.0% |
LGND Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $38.49M(+0.3%) |
| Dec 2024 | $38.38M(+16.6%) | $38.38M(+11.8%) |
| Sep 2024 | - | $34.32M(-8.4%) |
| Jun 2024 | - | $37.48M(+31.8%) |
| Mar 2024 | - | $28.43M(-13.6%) |
| Dec 2023 | $32.92M(+8.2%) | $32.92M(-8.6%) |
| Sep 2023 | - | $36.00M(+28.6%) |
| Jun 2023 | - | $27.99M(-4.1%) |
| Mar 2023 | - | $29.19M(-4.1%) |
| Dec 2022 | $30.42M(-64.4%) | $30.42M(-53.3%) |
| Sep 2022 | - | $65.17M(+4.6%) |
| Jun 2022 | - | $62.31M(+49.1%) |
| Mar 2022 | - | $41.80M(-51.1%) |
| Dec 2021 | $85.45M(+50.3%) | $85.45M(+32.8%) |
| Sep 2021 | - | $64.34M(+10.6%) |
| Jun 2021 | - | $58.16M(+6.8%) |
| Mar 2021 | - | $54.44M(-4.2%) |
| Dec 2020 | $56.85M(+87.1%) | $56.85M(+72.8%) |
| Sep 2020 | - | $32.91M(-21.4%) |
| Jun 2020 | - | $41.87M(+6.0%) |
| Mar 2020 | - | $39.51M(+30.0%) |
| Dec 2019 | $30.39M(-45.6%) | $30.39M(+38.4%) |
| Sep 2019 | - | $21.96M(+8.4%) |
| Jun 2019 | - | $20.26M(-23.9%) |
| Mar 2019 | - | $26.61M(-52.3%) |
| Dec 2018 | $55.85M(+118.2%) | $55.85M(+18.9%) |
| Sep 2018 | - | $46.98M(+11.8%) |
| Jun 2018 | - | $42.00M(+13.2%) |
| Mar 2018 | - | $37.11M(+45.0%) |
| Dec 2017 | $25.60M(+74.1%) | $25.60M(+99.7%) |
| Sep 2017 | - | $12.82M(-4.8%) |
| Jun 2017 | - | $13.46M(+90.8%) |
| Mar 2017 | - | $7.06M(-52.0%) |
| Dec 2016 | $14.70M(+138.2%) | $14.70M(+123.2%) |
| Sep 2016 | - | $6.59M(-33.9%) |
| Jun 2016 | - | $9.97M(-15.4%) |
| Mar 2016 | - | $11.78M(+90.9%) |
| Dec 2015 | $6.17M(-51.2%) | $6.17M(+11.8%) |
| Sep 2015 | - | $5.52M(-0.3%) |
| Jun 2015 | - | $5.53M(-25.5%) |
| Mar 2015 | - | $7.42M(-41.2%) |
| Dec 2014 | $12.63M(+468.6%) | $12.63M(+117.4%) |
| Sep 2014 | - | $5.81M(+85.5%) |
| Jun 2014 | - | $3.13M(-33.0%) |
| Mar 2014 | - | $4.67M(+110.3%) |
| Dec 2013 | $2.22M | $2.22M(-59.7%) |
| Sep 2013 | - | $5.51M(+687.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $699.00K(-84.9%) |
| Mar 2013 | - | $4.62M(+0.7%) |
| Dec 2012 | $4.59M(-24.9%) | $4.59M(+112.7%) |
| Sep 2012 | - | $2.16M(+164.0%) |
| Jun 2012 | - | $817.00K(-59.0%) |
| Mar 2012 | - | $1.99M(-67.4%) |
| Dec 2011 | $6.11M(+515.3%) | $6.11M(+255.4%) |
| Sep 2011 | - | $1.72M(+65.6%) |
| Jun 2011 | - | $1.04M(-24.9%) |
| Mar 2011 | - | $1.38M(+39.3%) |
| Dec 2010 | $993.00K(+60.7%) | $993.00K(+934.4%) |
| Sep 2010 | - | $96.00K(-99.0%) |
| Jun 2010 | - | $9.78M(+3180.9%) |
| Mar 2010 | - | $298.00K(-51.8%) |
| Dec 2009 | $618.00K(-94.4%) | $618.00K(-70.7%) |
| Sep 2009 | - | $2.11M(+101.0%) |
| Jun 2009 | - | $1.05M(-61.3%) |
| Mar 2009 | - | $2.71M(-75.2%) |
| Dec 2008 | $10.96M(-4.9%) | $10.96M(>+9900.0%) |
| Sep 2007 | - | $14.00K(-72.0%) |
| Jun 2007 | - | $50.00K(-96.1%) |
| Mar 2007 | - | $1.27M(-89.0%) |
| Dec 2006 | $11.52M(-45.0%) | $11.52M(+62.8%) |
| Sep 2006 | - | $7.08M(-62.1%) |
| Jun 2006 | - | $18.67M(-6.9%) |
| Mar 2006 | - | $20.05M(-4.3%) |
| Dec 2005 | $20.95M(-32.1%) | $20.95M(-14.0%) |
| Sep 2005 | - | $24.38M(+16.0%) |
| Jun 2005 | - | $21.02M(+14.7%) |
| Mar 2005 | - | $18.32M(-40.6%) |
| Dec 2004 | $30.85M(+63.2%) | $30.85M(+0.9%) |
| Sep 2004 | - | $30.58M(+70.5%) |
| Jun 2004 | - | $17.94M(+26.4%) |
| Mar 2004 | - | $14.19M(-25.0%) |
| Dec 2003 | $18.90M(+55.2%) | $18.90M(+90.5%) |
| Sep 2003 | - | $9.92M(+29.1%) |
| Jun 2003 | - | $7.69M(-55.0%) |
| Mar 2003 | - | $17.09M(+40.3%) |
| Dec 2002 | $12.18M(+24.3%) | $12.18M(+73.9%) |
| Sep 2002 | - | $7.00M(-48.1%) |
| Jun 2002 | - | $13.50M(+78.3%) |
| Mar 2002 | - | $7.57M(-22.7%) |
| Dec 2001 | $9.80M(-23.6%) | $9.80M(+52.3%) |
| Sep 2001 | - | $6.43M(+24.6%) |
| Jun 2001 | - | $5.16M(+5.1%) |
| Mar 2001 | - | $4.91M(-61.7%) |
| Dec 2000 | $12.82M | $12.82M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual accounts receivable?
- What is the all time high annual accounts receivable for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual accounts receivable?
The current annual accounts receivable of LGND is $38.38M
What is the all time high annual accounts receivable for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual accounts receivable is $85.45M
What is Ligand Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
Over the past year, LGND annual accounts receivable has changed by +$5.46M (+16.58%)
What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable?
The current quarterly accounts receivable of LGND is $38.49M
What is the all time high quarterly accounts receivable for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly accounts receivable is $85.45M
What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
Over the past year, LGND quarterly accounts receivable has changed by +$10.06M (+35.37%)